By Fineline Cube 
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection) — co‑developed and commercialized in Mainland China with Amgen (NASDAQ: AMGN) — has officially entered clinical use. As of August 10, medical institutions across 17 cities in China have issued prescriptions for tarlatamab, totaling 29 medical institutions.
Commercial Launch Overview
| Item | Detail |
|---|---|
| Product | Imdelltra (tarlatamab for injection) |
| Partners | BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) × Amgen (NASDAQ: AMGN) |
| China Commercial Supply Launch | 7 Aug 2026 |
| Clinical Use Confirmed | 11 Aug 2026 (prescriptions as of 10 Aug 2026) |
| Initial Coverage | 17 cities, 29 medical institutions issuing prescriptions |
| Initial Batch Target | 80 cities nationwide; 200+ medical institutions |
| Indication | Adult patients with previously treated extensive‑stage small cell lung cancer (ES‑SCLC) |
| Distinction | First and currently only approved T‑cell engager (TCE) targeting DLL3 and CD3 |
Prescribing Institutions
Medical institutions across 17 cities in China have issued prescriptions for tarlatamab as of August 10, including:
- Shanghai Chest Hospital
- Shanghai Pulmonary Hospital
- Fudan University Shanghai Cancer Center
- Cancer Hospital, Chinese Academy of Medical Sciences
- Peking University Cancer Hospital
- Beijing GoBroad Hospital
- Sun Yat‑sen University Cancer Center
In total, 29 medical institutions have prescribed the therapy to date.
Drug Profile & Mechanism of Action
- Molecule: Tarlatamab (Imdelltra), a T‑cell engager (TCE) bispecific antibody
- Targets: DLL3 (expressed on small cell lung cancer cells) and CD3 (on T cells)
- Mechanism: Bridges DLL3‑expressing tumor cells with T cells, redirecting the patient’s own immune system to kill SCLC cells
- First‑in‑Class Status: The first and currently only approved TCE targeting DLL3 and CD3, with no competing TCE in this class currently approved
- Indication: Treatment of adult patients with previously treated extensive‑stage small cell lung cancer (ES‑SCLC)
Rollout Plan
| Phase | Coverage |
|---|---|
| Current (as of 10 Aug 2026) | 17 cities, 29 prescribing medical institutions |
| Initial Batch Rollout | 80 cities nationwide, 200+ medical institutions |
Strategic Rationale & Market Impact
- First‑Mover Advantage: As the first and only approved DLL3/CD3 T‑cell engager, tarlatamab faces no direct in‑class competition in China, positioning it to define the standard of care for previously treated ES‑SCLC.
- High Unmet Need: Extensive‑stage SCLC carries a poor prognosis, with limited treatment options after first‑line therapy — a setting where improved survival outcomes represent significant clinical value.
- Rapid Commercial Scale‑Up: Moving from commercial supply launch (7 Aug) to prescriptions in 17 cities within days, with an initial batch covering 80 cities and 200+ institutions, signals strong hospital‑access momentum.
- Partnership Validation: The launch underscores the commercial execution of the BeOne–Amgen collaboration in Mainland China, combining Amgen’s global development heritage with BeOne’s local commercial infrastructure.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding tarlatamab’s commercial rollout, hospital coverage expansion, and clinical adoption in China. Actual results may differ due to risks including market access, reimbursement dynamics, and competitive developments.-Fineline Info & Tech